Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study
- PMID: 12490535
- DOI: 10.1093/hmg/ddg009
Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study
Abstract
Excess of nitric oxide (NO) has been shown to exert neurotoxic impacts in the brain. Moreover, inhibition of two NO-synthesizing enzymes, neuronal NOS (nNOS) and inducible NOS (iNOS), displays neuroprotective effects in the MPTP model of Parkinson's disease (PD). These data suggest a possible involvement of NOS as factors controlling the resistance of the nigral dopaminergic neurons to environmental insults. Therefore, we investigated whether polymorphisms present in these genes could contribute to the risk of developing PD. We carried out a community-based case-control study among subjects enrolled in the Mutualité Sociale Agricole, the French health insurance organization for workers connected to agriculture. Two-hundred and nine PD patients and 488 controls of European (mostly French) ancestry and matched for age, sex and region of residency were included in this study. Associations were observed with polymorphisms present in exon 22 of iNOS (OR for AA carriers=0.50, 95% CI=0.29-0.86, P=0.01) and in exon 29 of nNOS (OR for carriers of the T allele=1.53, 95% CI=1.08-2.16, P=0.02); no association was observed with a polymorphism in exon 18 of nNOS (OR for carriers of the T allele=1.20, 95% CI=0.85-1.69, P=0.30). Moreover, a significant interaction of the nNOS polymorphisms with current and ever cigarette smoking was found (nNOS 18, P=0.05; nNOS 29, P=0.04). All together, these data favour an involvement of these two genes as new modifier genes in PD.
Similar articles
-
Association of Polymorphism of Neuronal Nitric Oxide Synthase Gene with Risk to Parkinson's Disease.Mol Neurobiol. 2016 Jul;53(5):3309-3314. doi: 10.1007/s12035-015-9274-3. Epub 2015 Jun 17. Mol Neurobiol. 2016. PMID: 26081147
-
Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease.Nitric Oxide. 2000 Oct;4(5):534-9. doi: 10.1006/niox.2000.0288. Nitric Oxide. 2000. PMID: 11020342
-
Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder.J Affect Disord. 2011 Mar;129(1-3):175-82. doi: 10.1016/j.jad.2010.09.005. J Affect Disord. 2011. PMID: 20888049
-
Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.Antioxid Redox Signal. 2003 Jun;5(3):319-35. doi: 10.1089/152308603322110896. Antioxid Redox Signal. 2003. PMID: 12880486 Review.
-
Nitric oxide in neurodegeneration.Prog Brain Res. 1998;118:215-29. doi: 10.1016/s0079-6123(08)63210-0. Prog Brain Res. 1998. PMID: 9932444 Review.
Cited by
-
Nitric Oxide Involvement in Cardiovascular Dysfunctions of Parkinson Disease.Front Pharmacol. 2022 Jul 11;13:898797. doi: 10.3389/fphar.2022.898797. eCollection 2022. Front Pharmacol. 2022. PMID: 35899105 Free PMC article. Review.
-
Genetic polymorphisms in nitric oxide synthase genes modify the relationship between vegetable and fruit intake and risk of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1429-38. doi: 10.1158/1055-9965.EPI-09-0001. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19423521 Free PMC article.
-
Mitochondria: A Therapeutic Target for Parkinson's Disease?Int J Mol Sci. 2015 Sep 1;16(9):20704-30. doi: 10.3390/ijms160920704. Int J Mol Sci. 2015. PMID: 26340618 Free PMC article. Review.
-
Association of neuronal nitric oxide synthase C276T polymorphism with Alzheimer's disease.J Neurol. 2005 Aug;252(8):985-6. doi: 10.1007/s00415-005-0783-2. Epub 2005 Mar 17. J Neurol. 2005. PMID: 15765269 No abstract available.
-
The expanding roles of neuronal nitric oxide synthase (NOS1).PeerJ. 2022 Jul 7;10:e13651. doi: 10.7717/peerj.13651. eCollection 2022. PeerJ. 2022. PMID: 35821897 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical